3,996 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Csenge Advisory Group

Csenge Advisory Group acquired a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 3,996 shares of the company’s stock, valued at approximately $730,000.

Several other large investors also recently modified their holdings of AXSM. Wellington Management Group LLP grew its holdings in shares of Axsome Therapeutics by 84.1% in the third quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock worth $162,082,000 after acquiring an additional 609,516 shares during the period. Invesco Ltd. grew its holdings in shares of Axsome Therapeutics by 73.3% in the third quarter. Invesco Ltd. now owns 990,557 shares of the company’s stock worth $120,303,000 after acquiring an additional 419,008 shares during the period. Adage Capital Partners GP L.L.C. grew its holdings in shares of Axsome Therapeutics by 831.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 447,000 shares of the company’s stock worth $46,662,000 after acquiring an additional 399,000 shares during the period. Marshall Wace LLP grew its holdings in shares of Axsome Therapeutics by 566.5% in the third quarter. Marshall Wace LLP now owns 378,024 shares of the company’s stock worth $45,911,000 after acquiring an additional 321,308 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Axsome Therapeutics by 6.0% in the third quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock worth $507,739,000 after acquiring an additional 235,626 shares during the period. Institutional investors own 81.49% of the company’s stock.

Insider Transactions at Axsome Therapeutics

In other news, COO Mark L. Jacobson sold 233 shares of Axsome Therapeutics stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $228.18, for a total value of $53,165.94. Following the sale, the chief operating officer directly owned 4,517 shares of the company’s stock, valued at approximately $1,030,689.06. The trade was a 4.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Ari Maizel sold 7,500 shares of Axsome Therapeutics stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $182.42, for a total value of $1,368,150.00. Following the completion of the sale, the insider directly owned 7,500 shares in the company, valued at $1,368,150. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 72,628 shares of company stock valued at $12,205,662. 20.60% of the stock is currently owned by insiders.

Axsome Therapeutics Price Performance

Shares of Axsome Therapeutics stock opened at $230.62 on Thursday. The stock’s 50-day simple moving average is $184.96 and its 200-day simple moving average is $170.69. Axsome Therapeutics, Inc. has a 52 week low of $96.09 and a 52 week high of $235.91. The company has a market capitalization of $11.87 billion, a price-to-earnings ratio of -61.83 and a beta of 0.59. The company has a quick ratio of 1.32, a current ratio of 1.39 and a debt-to-equity ratio of 2.27.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.41). Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The firm had revenue of $191.20 million during the quarter, compared to the consensus estimate of $191.10 million. The firm’s revenue for the quarter was up 57.4% compared to the same quarter last year. As a group, analysts expect that Axsome Therapeutics, Inc. will post -2.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the company. Deutsche Bank Aktiengesellschaft set a $280.00 price objective on Axsome Therapeutics in a report on Tuesday, May 5th. Morgan Stanley lifted their target price on Axsome Therapeutics from $217.00 to $242.00 and gave the company an “equal weight” rating in a research report on Tuesday, May 5th. Wolfe Research assumed coverage on Axsome Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $230.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Monday, April 20th. Finally, UBS Group lifted their target price on Axsome Therapeutics from $251.00 to $259.00 and gave the company a “buy” rating in a research report on Friday, April 10th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $251.26.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.